Table depicting prevalence of common extraintestinal manifestations seen in the CD and UC groups.

Source publication

Clinical Profile of Patients Treated for Inflammatory Bowel Disease in A Tertiary Care Hospital in South India-A cross- sectional study

Article

Full-text available

Apr 2021

Illustrating drug survival of second line biological treatment at 12 months

Letter: vedolizumab or a second anti‐TNF—no difference in efficacy for primary biologic failures with IBD

Article

Full-text available

Apr 2021

LINKED CONTENT This article is linked to Rundquist et al papers. To view these articles, visit https://doi.org/10.1111/apt.16193 and https://doi.org/10.1111/apt.16352

Figure 2: Absorption spectra of galactose (green), MP (purple), Ag NPs...

Figure 3: IR spectra of MP, galactose, galactose-assisted Ag NPs, and...

Figure 4: Particle size distribution histogram of galactose-assisted Ag...

Figure 6: Dynamic light scattering histograms of galactose-assisted Ag...

Figure 7: X-ray diffraction patterns of galactose (a), Ag NPs (b),...

Drug-Loaded Silver Nanoparticles-A Tool for Delivery of a Mebeverine Precursor in Inflammatory Bowel Diseases Treatment

Chapter

Full-text available

Sep 2023

Diagnostic accuracy of bowel ultrasonography in patients with inflammatory bowel disease: a systematic review and meta-analysis

Article

Full-text available

Jan 2023

Sheza Malik

CARMIL-2 Gene Mutation A Novel Cause of Pediatric Monogenic Inflammatory Bowel Disease

Article

Full-text available

Nov 2023

http://www.tropicalgastro.com/articles/44/2/CARMIL-2-Gene-Mutation.html

Indicaciones y complicaciones de la cirugía en enfermedad inflamatoria intestinal

Article

Full-text available

Jul 2023